S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
S&P 500   4,217.96 (+0.30%)
DOW   33,070.15 (-0.07%)
QQQ   353.05 (+1.33%)
AAPL   177.98 (+1.45%)
MSFT   333.41 (+0.16%)
META   265.14 (+1.18%)
GOOGL   124.11 (-0.40%)
AMZN   122.54 (+2.02%)
TSLA   204.20 (+5.71%)
NVDA   406.60 (+4.40%)
NIO   7.84 (+1.82%)
BABA   80.33 (-0.79%)
AMD   128.97 (+1.53%)
T   15.47 (-0.19%)
F   12.71 (+5.13%)
MU   73.55 (-0.51%)
CGC   0.87 (-0.59%)
GE   101.50 (-1.21%)
DIS   88.25 (-0.05%)
AMC   4.66 (+0.43%)
PFE   37.11 (-1.30%)
PYPL   60.91 (+1.15%)
NFLX   396.05 (+4.53%)
NASDAQ:ACRV

Acrivon Therapeutics (ACRV) Stock Forecast, Price & News

$12.12
-0.43 (-3.43%)
(As of 09:35 AM ET)
Compare
Today's Range
$12.12
$12.86
50-Day Range
$8.38
$14.09
52-Week Range
$8.06
$25.47
Volume
2,334 shs
Average Volume
55,945 shs
Market Capitalization
$265.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.60

Acrivon Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
86.5% Upside
$22.60 Price Target
Short Interest
Bearish
2.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Acrivon Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.76) to ($3.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

816th out of 1,009 stocks

Pharmaceutical Preparations Industry

410th out of 494 stocks


ACRV stock logo

About Acrivon Therapeutics (NASDAQ:ACRV) Stock

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3). The AP3 platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients predicted to benefit from its drug candidates. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is being advanced in a potentially registrational Phase 2 trial across various tumor types. It is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1 and PKMYT1. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Stock News Headlines

Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Q1 2023 Akoya Biosciences Inc Earnings Call
New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Acrivon Therapeutics Inc.
See More Headlines
Receive ACRV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acrivon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACRV Company Calendar

Last Earnings
3/28/2023
Today
5/30/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACRV
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.60
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+80.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.16 per share

Miscellaneous

Free Float
N/A
Market Cap
$275.22 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Peter Blume-Jensen M.D. (Age 61)
    Ph.D., Co-Founder, Chairman, CEO, Pres & Acting Chief Scientific Officer
    Comp: $645k
  • Ms. Kristina Masson Ph.D. (Age 43)
    Co-Founder, Exec. VP of Bus. Operations, Treasurer, Sec. & Director
  • Dr. Eric J. Devroe Ph.D. (Age 45)
    Chief Operating Officer
    Comp: $375k
  • Mr. Erick Gamelin M.D. (Age 66)
    Ph.D., Chief Medical Officer
    Comp: $480.72k
  • Mr. Rasmus Holm-Jorgensen (Age 52)
    Chief Financial Officer
  • Ms. Katharine Peterson CPA
    VP of Fin. & Accounting
  • Mr. Bruce Close
    VP of Quality & Compliance
  • Ms. Mary-Alice Miller J.D. (Age 49)
    Gen. Counsel
  • Ms. Crystal Mercado
    Global Head of HR
  • Dr. Jesper V. Olsen Ph.D.
    Academic Co-Founder, Head of Phosphoproteomics & Member of Scientific Advisory Board













ACRV Stock - Frequently Asked Questions

Should I buy or sell Acrivon Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acrivon Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACRV shares.
View ACRV analyst ratings
or view top-rated stocks.

What is Acrivon Therapeutics' stock price forecast for 2023?

7 equities research analysts have issued 12 month target prices for Acrivon Therapeutics' shares. Their ACRV share price forecasts range from $17.00 to $25.00. On average, they predict the company's share price to reach $22.60 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price.
View analysts price targets for ACRV
or view top-rated stocks among Wall Street analysts.

How have ACRV shares performed in 2023?

Acrivon Therapeutics' stock was trading at $11.52 at the beginning of 2023. Since then, ACRV shares have increased by 8.9% and is now trading at $12.55.
View the best growth stocks for 2023 here
.

When is Acrivon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ACRV earnings forecast
.

How were Acrivon Therapeutics' earnings last quarter?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) posted its quarterly earnings data on Tuesday, March, 28th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.10) by $0.30.

When did Acrivon Therapeutics IPO?

(ACRV) raised $100 million in an initial public offering on Tuesday, November 15th 2022. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

What is Acrivon Therapeutics' stock symbol?

Acrivon Therapeutics trades on the NASDAQ under the ticker symbol "ACRV."

When did the company's lock-up period expire?

Acrivon Therapeutics' lock-up period expired on Monday, May 15th. Acrivon Therapeutics had issued 7,550,000 shares in its initial public offering on November 15th. The total size of the offering was $94,375,000 based on an initial share price of $12.50. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Acrivon Therapeutics' major shareholders?

Acrivon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (4.05%), Federated Hermes Inc. (2.80%), BlackRock Inc. (2.16%), Geode Capital Management LLC (0.80%), State Street Corp (0.39%) and Charles Schwab Investment Management Inc. (0.27%). Insiders that own company stock include Ltd Chione and Ra Capital Management, LP.
View institutional ownership trends
.

How do I buy shares of Acrivon Therapeutics?

Shares of ACRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acrivon Therapeutics' stock price today?

One share of ACRV stock can currently be purchased for approximately $12.55.

How much money does Acrivon Therapeutics make?

Acrivon Therapeutics (NASDAQ:ACRV) has a market capitalization of $275.22 million.

How can I contact Acrivon Therapeutics?

The official website for the company is www.acrivon.com. The company can be reached via phone at 617-207-8979 or via email at asantos@wheelhouselsa.com.

This page (NASDAQ:ACRV) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -